Literature DB >> 17290462

Predicting the cost of Parkinson's disease.

Paul McCrone1, Liesl M Allcock, David J Burn.   

Abstract

The degenerative nature of Parkinson's disease (PD) suggests that it will lead to high levels of resource use. This study measures service use and costs for a representative community sample of PD patients and identifies cost predictors. Patients were identified from general practices and were interviewed twice, separated by a 12-month interval. Demographic and clinical data on patients were collected and 6-month costs were calculated. Regression analysis was used to identify significant baseline predictors of follow-up costs. The annual service costs (baseline and follow-up combined) were 13,804 pounds per person. Formal service costs accounted for 20% of this figure with informal care from families/friends accounting for 80%. The regression model explained 42% of total follow-up costs and significant predictors included gender (with men having higher costs), disability, and depression.

Entities:  

Mesh:

Year:  2007        PMID: 17290462     DOI: 10.1002/mds.21360

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.

Authors:  Yaroslav Winter; Maria Stamelou; Nicole Cabanel; Friedericke Sixel-Döring; Karla Eggert; Günter U Höglinger; Birgit Herting; Thomas Klockgether; Heinz Reichmann; Wolfgang H Oertel; Richard Dodel; Annika E Spottke
Journal:  J Neurol       Date:  2011-04-10       Impact factor: 4.849

Review 2.  Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.

Authors:  Samuel D Kim; Natalie E Allen; Colleen G Canning; Victor S C Fung
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

Review 3.  The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease.

Authors:  Angelo Antonini; Luisa Mirò; Carlo Castiglioni; Gianni Pezzoli
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

Review 4.  Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review.

Authors:  Nafsika Afentou; Johan Jarl; Ulf-G Gerdtham; Sanjib Saha
Journal:  Mov Disord Clin Pract       Date:  2019-04-11

5.  The size, burden and cost of disorders of the brain in the UK.

Authors:  Naomi A Fineberg; Peter M Haddad; Lewis Carpenter; Brenda Gannon; Rachel Sharpe; Allan H Young; Eileen Joyce; James Rowe; David Wellsted; David J Nutt; Barbara J Sahakian
Journal:  J Psychopharmacol       Date:  2013-07-24       Impact factor: 4.153

6.  Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.

Authors:  Esther Cubo
Journal:  Clinicoecon Outcomes Res       Date:  2010-09-06

7.  Costs of Parkinson's disease in a privately insured population.

Authors:  Scott J Johnson; Anna Kaltenboeck; Melissa Diener; Howard G Birnbaum; Elizabeth Grubb; Jane Castelli-Haley; Andrew D Siderowf
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

8.  Ability of a Set of Trunk Inertial Indexes of Gait to Identify Gait Instability and Recurrent Fallers in Parkinson's Disease.

Authors:  Stefano Filippo Castiglia; Antonella Tatarelli; Dante Trabassi; Roberto De Icco; Valentina Grillo; Alberto Ranavolo; Tiwana Varrecchia; Fabrizio Magnifica; Davide Di Lenola; Gianluca Coppola; Donatella Ferrari; Alessandro Denaro; Cristina Tassorelli; Mariano Serrao
Journal:  Sensors (Basel)       Date:  2021-05-15       Impact factor: 3.576

9.  Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.

Authors:  Katarzyna Smilowska; Daniel J van Wamelen; Tomasz Pietrzykowski; Alexander Calvano; Carmen Rodriguez-Blazquez; Pablo Martinez-Martin; Per Odin; K Ray Chaudhuri
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

10.  An exercise intervention to prevent falls in Parkinson's: an economic evaluation.

Authors:  Emily Fletcher; Victoria A Goodwin; Suzanne H Richards; John L Campbell; Rod S Taylor
Journal:  BMC Health Serv Res       Date:  2012-11-23       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.